Summary Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. At the time of diagnosis, a large percentage of NSCLC patients have already developed metastasis, responsible for extremely high mortality rates. CXCR4 receptor and focal adhesion kinase (FAK) are known to regulate such invasive cancer behavior. Their expression is downregulated by p53 and PTEN tumor suppressors which are commonly co-inactivated in NSCLC patients and contribute to metastasis. Therefore, targeting CXCR4 or FAK seems to be a promising strategy in suppressing metastatic spread of p53/PTEN deficient NSCLCs. In this study, we first examined the invasive characteristics of NSCLC cells with suppressed p53 and PTEN activity using wound healing, gelatin degradation and invasion assays. Further, changes in the expression of CXCR4 and FAK were evaluated by RT-qPCR and Western Blot analysis. Finally, we tested the ability of CXCR4 and FAK inhibitors (WZ811 and PF-573228, respectively) to suppress the migratory and invasive potential of p53/PTEN deficient NSCLC cells, in vitro and in vivo using metastatic models of human NSCLC. Our results showed that cells with mutually inactive p53 and PTEN have significantly increased invasive potential associated with hyperactivation of CXCR4 and FAK signaling pathways. Treatments with WZ811 and PF-573228 inhibitors significantly reduced migratory and invasive capacity in vitro and showed a trend of improved survival in vivo. Accordingly, we demonstrated that p53/PTEN deficient NSCLCs have extremely invasive phenotype and provided a rationale for the use of CXCR4 or FAK inhibitors for the suppression of NSCLC dissemination.
Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide with less than 18% 5-year patient survival rate [1] . At the time of diagnosis, about 70% of lung cancer patients are already at the advanced stage with metastases [2] . Even when diagnosed at the earliest stage, most of the patients already have micro-metastases [3] . Such frequent presence of lung cancer metastases significantly affects efficiency of conventional therapies and it is a major cause of treatment failure and high mortality rate associated with lung cancer [4] . Therefore, in the era of developing personalized cancer treatments, special efforts are focused on identifying novel targeted NSCLC therapies that could also interfere with the process of metastasis [5] .
Cancer cells with higher ability to metastasize are often characterized by altered expression of different marker proteins involved in adhesion, migration and invasion, such as CXCR4, FAK, and their related signaling molecules [6] . Chemokine receptor, CXCR4, is highly overexpressed in NSCLC and plays an important role in its pathogenesis, as well as in metastasis [7, 8] . CXCR4 exerts its biological effects, at least partially, by activating downstream phosphorylation of FAK, one of the key molecules in regulating cell Electronic supplementary material The online version of this article (doi:10.1007/s10637-017-0494-4) contains supplementary material, which is available to authorized users. adhesion and motility [9, 10] . Expression of both CXCR4 and FAK is negatively regulated by p53 and PTEN tumor suppressors [11] [12] [13] [14] . Apart from being among the most frequently mutated genes in NSCLC [15] , these two tumor suppressors have been found to be simultaneously altered in a significant number of NSCLC patients and associated with metastatic spread and dramatically shorter survival [16] . Although the individual contribution of these tumor suppressors in lung cancer metastasis is well known [17, 18] , the effect of their mutual inactivation has not been elucidated so far. Here we propose that p53 and PTEN might cooperatively regulate CXCR4 and FAK expression that seems to promote an extremely metastatic phenotype and that targeting CXCR4 or FAK may be a promising strategy in suppressing the metastatic spread of p53/PTEN deficient NSCLCs.
Therefore, we first examined the invasive capacities of NCI-H460 cells where the activity of p53 and PTEN was simultaneously pharmacologically inhibited and COR-L23 cells that have intrinsically inactive both tumor suppressors (http://cancer.sanger.ac.uk/cell_lines). We further evaluated the expression of CXCR4 and FAK and their downstream signaling molecules as common targets of p53 and PTEN activity and finally, tested the ability of CXCR4 and FAK inhibitors to suppress the migratory and invasive capacities of NSCLC cells, in vitro and in vivo. Our data showed that joint inactivation of p53 and PTEN in NSCLC cells resulted in an extremely invasive phenotype. The obtained results suggest, under the experimental conditions tested herein, that CXCR4 and FAK inhibitors could be a valuable targeted therapy towards inhibiting migration and invasion of p53/ PTEN deficient NSCLCs.
Materials and methods

Cells and cell cultures
NCI-H460 and COR-L23 cell lines were purchased from the American Type Culture Collection (ATCC, Rockville, MD) and European Collection of Cell Cultures (ECACC, Salisbury, UK), respectively. All the cells were maintained in RPMI 1640, supplemented with 10% FBS, 2 mM L-glutamine, 4.5 g/l glucose, 10,000 U/ml penicillin, 10 mg/ml streptomycin, 25 μg/ml amphotericin B solution at 37°C in a humidified 5% CO 2 atmosphere.
Drugs and treatments
CXCR4 antagonist WZ811, FAK inhibitor PF-573228 and p53 inhibitor Pifitrin-α (PFT-α) were obtained from Selleckchem (Houston, Texas, USA). PTEN inhibitor, b p V ( H O p i c ) , w a s p u r c h a s e d f r o m S a n t a C r u z Biotechnology (Dallas, USA). All inhibitors were disolved in DMSO (Sigma-Aldrich Chemie Gmbh, Germany) to 10 mM stocks and stored at −20°C. Before treatment, all drugs were freshly diluted in sterile water.
To achieve individual or simultaneous inactivation of p53 and PTEN tumor suppressors, NCI-H60 cells were treated with 10 μM PFT-α and 2.5 μM bpV(HOpic), alone and in combination, for 24 h. Drugs were administered 24 h after cell seeding. Cells treated with PFT-α and bpV(HOpic), alone and in combination, from here on are designated as NCI-H460 p53-, NCI-H460 PTEN-and NCI-H460 p53-/PTEN-cells, respectively. To evaluate the effects of FAK and CXCR4 inhibitors, NCI-H460 p53-/PTEN-and COR-L23 cells were treated with 1 μM PF-573228 and 1 μM WZ811 for 24 h. In NCI-H460 p53-/PTEN-cells these treatments were administrated 2 h after the co-treatments with p53 and PTEN inhibitors.
RNA extraction and reverse transcription reaction
Total RNA was isolated using Trizol® reagent (Invitrogen Life Technologies, USA) according to the manufacturer's instructions. RNA was quantified by spectrophotometry and quality was determined by agarose gel electrophoresis. Reverse transcription reactions were performed using 2 μg of total RNA, with a High-capacity cDNA reverse transcription kit (Applied Biosystems, USA), following the manufacturers' instructions.
Quantitative real-time PCR
Quantitative real time PCR (qPCR) was used to analyze the differences in CXCR4, FAK and PTEN gene expression level. Reactions were performed by Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific, USA) on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, USA) according to the manufacturer's recommendations, using 100 ng cDNAs and primers specific for each gene and ACTB as internal control for normalization [19] [20] [21] [22] . Each sample was tested in triplicate and relative gene expression was analyzed by 2 −ΔΔCt method [23] . I m m u n o r e a c t i v i t y w a s d e t e c t e d b y e n h a n c e d chemiluminiscence (ECL, GE Healthcare) and exposed to film (Kodak Biomax). Each blot was re-probed with a primary mouse β-actin (1:5000; Santa Cruz, sc-8432) and GAPDH (1/5000; Biolegend, 649202) antibody and incubated with an anti-mouse secondary antibody (1:10,000; Cell Signaling, 7076S). All antibodies were diluted in TBST. Signals were quantified by densitometry using Image Quant software (v. 5.2, GE Healthcare) and expressed as relative values (i.e., density ratio normalized to the corresponding internal control, β-actin or GAPDH signal).
Wound healing assay
In order to evaluate the migratory potential cells were seeded in 24-well plates and grown for 24 h. Upon reaching confluence, a uniform wound was scratched into a monolayer of each well with a sterile plastic 200 μl micropipette tip. After wounding, tissue culture medium was replaced and described treatments were applied. Wound closure was monitored by imaging cells at 2× magnification on a Leica microscope (Leica Microsystems GmbH, Wetzlar, Germany) immediately and 24 h after wounding. The captured images were analyzed by ImageJ software (NIH, USA) to measure the degree of closure of the wounded area. Independent experiments were performed at least three times. A control sample without 10% FBS, as a measurement of spontaneous cell invasion, was included in each experiment. After the incubation, cells that invaded through the Matrigel and its underlying membrane were fixed in 4% paraformaldehyde-PBS and stained with Hoechst 33342. The cells that failed to invade remained on the upper surface and were carefully removed with a cotton swab, whereas the cells on the lower surface of the membranes were counted under a Zeiss Axiovert inverted fluorescent microscope at a 10× magnification. The average number of cells in 30 independent fields per membrane was analyzed. At least 3 independent experiments were performed. The results are presented as percentage of cells that invaded through the matrigel-coated membrane compared to the untreated control.
Gelatin degradation assay
In vivo tumorigenicity assays
Eight weeks old NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice and 8-10 week-old SCID (Severe Combined Immunodeficiency) mice were used for in vivo experiments. All animal procedures were in compliance with Directive (2010/63/EU) on the protection of animals used for experimental and other scientific purposes and were approved by the IACUC and the local Directorate-General for Regional Rural Economy and Veterinary (Lisence No 5542/228006). All mice were housed under pathogen-free conditions in the animal facility in a controlled environment (12 h dark/light cycles), fed with standard laboratory chow, and given autoclaved water.
For the in vivo tumorigenicity assays, subcutaneous injections were performed in each axillary region of the rear flanks. On the day of inoculation, NCI-H460 and COR-L23 cells were counted and diluted in 100 μl RPMI medium. Two different inoculation densities (100,000 and 10,000 cells) for both cell lines were used in NSG mice to evaluate their tumorigenic potential. Formation of palpable tumors was monitored over time.
To investigate the growth rate of NCI-H460 and COR-L23 cells derived xenografts 10 6 cells of each cell line were injected in SCID mice. Mice were monitored three times a week for tumor growth. Tumor size was measured with a caliper and tumor volume was calculated using the formula V (mm3) = a × b 2 /2, where V (mm3) is the tumor volume in mm3, a = length and b = width of the tumors. Each group in both types of in vivo experiments consisted of 3 mice, with 2 inocula per mice. The experiments were terminated when the tumor size reached a volume of 1500 mm 3 (about 11% of the mouse weight).
Orthotopic metastatic xenograft model
The model was established following the procedure described by Kraus-Berthier et al. [24] . Briefly, animals were anesthetized with Ketamin (Imalgene 1000, Merial) at 10 mg/kg and Xylazin (Sedaxylan, EuroVet) at 2 mg/kg, administered i.p. On the day of inoculation, NCI-H460 and COR-L23 cells were counted and diluted in 100 μl RPMI medium. NCI-H460 and COR-L23 cells were implanted at 1 × 10 6 and 5 × 10 5 inoculation densities through the chest wall into the left pleural space of SCID mice (i.pl.) in a volume of 100 μl using a 26 gauge needle. Each group consisted of 5 mice. One mouse from each group was sacrificed on day 14 to evaluate metastatic spread of NCI-H460 and COR-L23 derived tumors.
In vivo antitumor activity
Vehicle control and both inhibitors, PF-573228 and WZ811, diluted in WFI (water for injection) with 10% DMSO and 5% Tween 80, were administered i.p. 5 days in a row to NCI-H460-and COR-L23-bearing mice, starting 7 days after cell inoculation. Each treated group consisted of 4 mice, and control groups consisted of 7 mice. Animal mortality was checked daily, and the antitumor activity was evaluated comparing survival times.
Statistical analysis
Statistical analyses were performed by GraphPad Prism 6. The data obtained by qRT-PCR, wound healing, invasion tests, Western blotting and in vivo experiments were analyzed by Student t-test. Gelatin degradation data did not have a normal distribution, so the Wilcoxon matched-pairs signed rank test was carried out. Survival analyses were performed using Kaplan and Meier product-limit method. The log rank test was used to assess the significance of the difference between pairs of survival probabilities. The observed differences were considered statistically significant if p < 0.05.
Results p53 and PTEN inhibition and functional status assessment in NSCLC cell lines
To test whether activities of p53 and PTEN tumor suppressors simultaneously influenced cell invasion, we pharmacologically inactivated p53 and PTEN in NCI-H460 cell line that is a wild type for both tumor suppressors (http://cancer.sanger.ac. uk/cell_lines). We used the well-known inhibitor of p53 (Pifitrin-α, PFT-α) in a 10 μM concentration previously shown to be efficient in NCI-H460 cells [25] . The efficacy of PTEN inhibitor (bpV(HOpic)) was determined by analyzing the level of pAKT in NCI-H460 cells treated with 1 μM and 2.5 μM bpV(HOpic). Western blot analyses have shown that 2.5 μM bpV(HOpic) successfully inhibited activity of PTEN by increasing AKT phosphorylation 1.7 fold compared to untreated NCI-H460 cells ( Fig. 1a ; p = 0.02). Combined treatment with 10 μM PFT-α and 2.5 μM bpV(HOpic) did not have anti-proliferative effect on NCI-H460 cells, as shown in Online Resource 1a.
Additionally, we used COR-L23 cell line with intrinsically mutated and inactivated p53 (http://cancer.sanger.ac.uk/cell_ lines). By comparing PTEN gene expression level between COR-L23 and NCI-H460 cells using qRT-PCR, we demonstrated that COR-L23 cells have innately suppressed PTEN function. Namely, COR-L23 cells showed 11.5-fold decreased expression of PTEN compared to NCI-H460 cells ( Fig. 1b ; p = 0.0002). Such difference in PTEN expression between these two cell lines affected the level of pAKT protein as assessed by Western blot analysis. The level of pAKT in COR-L23 cells was increased 6.8 fold compared to NCI-H460 cells ( Fig. 1c ; p = 0.0003).
Increased invasive potential of NSCLC cell lines with mutually inactivated p53 and PTEN
To examine whether the simultaneous inhibition of p53 and PTEN influenced invasive capacity of NCI-H460 cells, we analyzed migration and invasion of these cells treated with 10 μM PFT-α and 2.5 μM bpV(HOpic), alone (NCI-H460 p53-and NCI-H460 PTEN-cells, respectively) and in combination (NCI-H460 p53-/PTEN-cells) using wound healing, invasion and gelatin degradation assays. Specifically, only combined treatment with PFT-α and bpV(HOpic) significantly increased cell migration in the wound healing assay 1.4-fold ( Fig. 2a; p = 0.0052) compared to untreated cells. In invasion and gelatin degradation assays, we observed greater capacity of NCI-H460 cells to invade matrigel ( Fig. 2b; 1.7-fold; p = 0.0043) and degrade gelatin ( Fig. 2c; 1.9-fold; p = 0.0003) after functional inhibition of p53 and PTEN.
Moreover, COR-L23 cells with mutated p53 and significantly lower expression of PTEN showed a similar pattern of migration and invasion to NCI-H460 cells with these two Fig. 1 PTEN inhibition (Fig. 2) . More precisely, COR-L23 cells migrated at 4 times higher rate than untreated NCI-H460 cells ( Fig. 2a ; p = 0.0005), exhibited a 2-fold increase in invasion through matrigel ( Fig. 2b ; p = 0.0022) and had a 2.4-fold increase in degradation of gelatin ( Fig. 2c ; p = 0.0001).
Importantly, NCI-H460
p53-/PTEN-and COR-L23 cells, both with dual p53 and PTEN inactivation, had also significantly increased invasion and gelatin degradation compared to NCI-H460 cells with individually inhibited p53 and PTEN, as pointed out in Fig. 2b and c. This was also true for the migratory capacity of COR-L23 cells (Fig. 2a) . Fig. 3a ; p = 0.047) and 2-fold ( Fig. 3a ; p = 0.022), compared to untreated cells, respectively. In contrast, the FAK mRNA expression level remained unchanged upon all treatments in NCI-H460 cell line (Fig. 3b) . COR-L23 cells had significantly increased expression of CXCR4 and FAK mRNAs compared to NCI-H460 cells 3.1-fold ( Fig. 3a ; p = 0.008) and 1.7-fold ( Fig. 3b ; p = 0.01), respectively. On protein level, simultaneous functional inhibition of p53 and PTEN in NCI-H460 cells significantly increased CXCR4 level 2.7 fold ( Fig. 4a ; p = 0.0046) and induced FAK activation 1.7-fold ( Fig. 4b ; p = 0.007). In addition, we found that functional inhibition of p53 and PTEN in NCI-H460 cells, alone and in combination, led to significant changes in the level of pAKT compared to untreated NCI-H460 cells (Fig. 4c) . More precisely, NCI-H460 p53-and NCI-H460 PTEN-cells showed significant increase in AKT phosphorylation 1.7 fold (p = 0.003) and 1.7-fold (p = 0.004) compared to NCI-H460 cells, respectively. Most importantly, NCI-H460 p53-/PTEN-cells had the most pronounced effect on the AKT phosphorylation with 3-fold increase compared to NCI-H460 cells ( Fig. 4c; p = 0.001) . pERK level was changed only in NCI-H460 p53-/PTEN-cells exhibiting 2.7-fold increase compared to untreated NCI-H460 cells ( Fig. 4d ; p = 0.042).
Level of CXCR4 and activation of FAK, AKT and ERK was significantly increased in COR-L23 compared to NCI-H460 cells 5.2 fold (Fig. 4a ; p = 0.001), 2.1-fold ( Fig. 4b ; p = 0.015), 6.8-fold ( Fig. 4c ; p = 0.002) and 3-fold ( Fig. 4d ; p = 0.037), respectively.
FAK and CXCR4 inhibitors suppressed invasiveness of NSCLC cell lines with inactivated p53 and PTEN tumor suppressors
To evaluate whether NSCLC cells with mutual inactivation of p53 and PTEN (NCI-H460 p53-/PTEN-and COR-L23) could be responsive to FAK and CXCR4 inhibition, cells were treated with PF-573228 (FAK inhibitor) and WZ811 (CXCR4 inhibitor) and the changes in their invasive properties were analyzed. Both inhibitors, used in 1 μM concentrations, did not have considerable anti-proliferative effects on NCI-H460 (Fig. 5a ). More pronounced effects of the treatments were observed in invasion and gelatin degradation assays.
NCI-H460
p53-/PTEN-cells treated with PF-573228 and WZ811 had a significantly decreased invasion capacity, 4.7 ( Fig. 5b ; p = 0.0002) and 6.2 ( Fig. 5b ; p = 0.0001) fold, respectively. In addition, NCI-H460 p53-/PTEN-cells treated with PF-573228 and WZ811 degraded gelatin significantly Fig. 5c ; p = 0.0001) and 5.1 ( Fig. 5c ; p = 0.0001) fold, respectively.
The invasive behavior of COR-L23 cells upon PF-573228 and WZ811 treatments was similar to that observed in NCI-
H460
p53-/PTEN-cells treated with FAK and CXCR4 inhibitors. According to wound healing assay, COR-L23 cells treated with 1 μM PF-573228 migrated at 1.6 times slower rate than untreated cells ( Fig. 5d ; p = 0.037), while COR-L23 cells treated with 1 μM PF-573228 and 1 μM WZ811 exhibited 2.8-fold (Fig. 5e; p = 0.0001) and 2.6-fold (Fig. 5e ; p = 0.0001) decrease in invasion, respectively. In addition, COR-L23 cells treated with 1 μM PF-573228 and 1 μM WZ811 degraded gelatin 2.2-fold ( Fig. 5f ; p = 0.0001) and 2.5-fold ( Fig. 5f ; p = 0.0001) more than untreated cells, respectively.
Downregulation of pFAK and pAKT level in NSCLC cell lines treated with FAK and CXCR4 inhibitors
To examine molecular changes after the treatments with PF-573228 and WZ811 we analyzed level of pFAK, pAKT and pERK in untreated and treated NCI-H460 p53-/PTEN-and COR-L23 cells. NCI-H460 p53-/PTEN-cells treated with PF-573228 and WZ811 exhibited significant reduction in FAK phosphorylation, 2.6-fold ( Fig. 6a ; p = 0.0001) and 2.1-fold ( Fig. 6a ; p = 0.0001), respectively. In addition, both PF-573228 and WZ811 treatments, led to a 2.6-fold decrease of pAKT in NCI-H460 Fig. 6b ; p = 0.0015 and p = 0.0008, respectively). However, neither treatment caused pERK changes in NCI-H460 p53-/PTEN-cells (Fig. 6c) . COR-L23 cells treated with PF-573228 exhibited significant reduction in the phosphorylation of FAK and AKT, 2-fold (p = 0.0018) and 1.5-fold (p = 0.015), respectively, while WZ811 did not change the level of these proteins (Fig. 6d  and e) . The level of pERK remained unchanged upon both treatments in COR-L23 cells (Fig. 6f) .
In vivo tumorigenicity, metastatic spread and anti-invasive treatment of COR-L23 derived tumors
As we have shown that cells with inactivated p53 and PTEN exhibited more aggressive phenotype responsive to antiinvasive treatments with CXCR4 and FAK inhibitors, we further aimed to verify these findings in vivo. We first developed subcutaneous lung cancer human-to-mouse xenografts to compare the tumorigenicity of NCI-H460 and COR-L23 cells. Then, we investigated the invasive and metastatic potential of both cell lines in orthotropic metastatic lung carcinoma mouse models which we further used to test anti-invasive effects of CXCR4 and FAK inhibitors.
Tumorigenicity was followed after subcutaneous inoculation of 10,000 and 100,000 of either NCI-H460 or COR-L23 cells in NOD scid gamma (NSG) mice. In these models we observed that COR-L23 tumors were developed faster in both inoculation densities as compared to NCI-H460 tumors (Table 1 ). More specifically, first palpable tumor was noticed in COR-L23 xenografts at day 15 following 10,000 cells' p53-/PTEN-cells and (d) pFAK, (e) pAKT and (f) pERK in COR-L23 cells after treatments with PF-573228 and WZ811. The data are expressed as the level of phosphoprotein relative to total protein level, all normalized to β-actin or GAPDH, from at least three independent experiments and they are presented as mean value ± S.E. * indicates p < 0.05 compared to untreated cells. Each graph is accompanied by representative Western blot inoculation, while in NCI-H460 xenografts, the first tumor was observed at day 17 post cells' inoculation. Even greater difference was observed when 100,000 cells were inoculated. COR-L23 xenografts developed the first palpable tumor at day 9, while in NCI-H460 xenografts the first palpable tumor observed at day 14 after inoculation (Table 1) . Further to that, xenografts developed in SCID mice after inoculation of 10 6 cells of NCI-H460 or COR-L23 cell lines were used to evaluate tumor growth rate. Similar to the previous experiment, COR-L23 derived xenografts first formed palpable tumor, but after the 25th day NCI-H460 cells started to grow faster than COR-L23 cells and at the end of the experiment tumor derived from NCI-H460 was 1.5 volume of COR-L23 derived tumor (Fig. 7a) . However, t-test analysis did not show any statistically significant difference in NCI-H460 and COR-L23 derived tumor volume.
Further, we investigated the in vivo capacity of NCI-H460 and COR-L23 cells to invade lung parenchyma. NCI-H460 and COR-L23 cells were implanted in the pleural cavity of SCID mice to obtain an orthotopic metastatic tumor model. 1 × 10 6 and 5 × 10 5 tumor cells were inoculated into the pleural space and survival time was followed. Specifically, at 1 × 10 6 inoculation density there was no difference in survival between NCI-H460 and COR-L23 bearing animals (data not shown). However, at 5 × 10 5 inoculation density, we observed a trend of shorter survival time ( Fig. 7b ; p = 0.076) in animals bearing the COR-L23 tumor, with a median survival time of 24 days for COR-L23 tumors and 28 days for NCI-H460 tumors. Moreover, at day 14, the metastatic tumor progression in the pleural cavity was very aggressive for both cell lines, but in animals bearing the COR-L23 derived tumor distant metastases were seen in peritoneal organs, such as liver, colon and pancreas (Fig. 7c) .
Finally, we evaluated the potential of CXCR4 and FAK inhibitors to suppress a metastatic progression of COR-L23 derived tumor in orthotopic metastatic NSCLC model. Although no statistical analysis could be performed here due to the small group size, the results suggest that both PF-573228 and WZ811 demonstrated a trend of the life span increase in the tumor-bearing treated mice (Fig 7d) . Particularly, WZ811 was found to prolong the median survival by 4 days (20% increase, median survival for treated mice 24 days as compared to a median survival of 20 days for the vehicle treated mice that served as controls).
Discussion
NSCLC represents one of the most aggressive malignant diseases characterized by frequent and extensive appearance of metastases. A number of different genes drive the metastatic spread of NSCLC, including p53 and PTEN tumor suppressors that regulate important signaling pathways involved in the cell migration and invasion [17, 18] . These two tumor suppressors are among the most commonly inactivated genes in human cancers. Individually, they have very important roles in sustaining cellular homeostasis but they are also involved in complex regulatory interactions [26] . However, their simultaneous inactivation has different implications in pathogenesis of various cancer types [27] [28] [29] [30] . Specifically, co-inactivation of TP53 and PTEN has been shown to be a significant characteristic of NSCLC patients, particularly of those with a positive lymph node invasion [16] . Nevertheless, their cooperative role in promoting the metastatic phenotype of NSCLC has not been studied so far.
To test the effects of simultaneous inactivation of p53 and PTEN tumor suppressors on invasive characteristics of NSCLC cells, we used the NCI-H460 large cell carcinoma line that expresses wild type p53 and PTEN which we subsequently pharmacologically inhibited using the well-known inhibitors PFT-α and/or bpV(HOpic), respectively. Specificity and efficacy of the applied inhibitors at used concentrations have been reported in previous publications [25, 31] . Additionally, we employed another large cell lung carcinoma cell line, COR-L23, as a model with intrinsically suppressed function of both tumor suppressors. In accordance with previously published clinical data [16] , COR-L23 and p53/PTEN deficient NCI-H460 cells exhibited the most aggressive phenotype. These cells had significantly higher ability to migrate, invade and degrade gelatin compared to the wild type cells, as well as cells with individually inactivated single tumor suppressors. Similarly, a recent study on glioblastoma cell lines has shown that p53/PTEN deficient cells exhibited the highest invasive potential through matrix and underlying porous membrane [32] . Moreover, p53 and PTEN were shown to have cooperative anti-invasive effects in Src-transformed vascular smooth muscle cells and fibroblasts by antagonizing Src/ Stat3 pathway and repressing Src-induced podosome formation [33, 34] . In addition, our results show more pronounced invasive phenotype of COR-L23 cells compared to NCI-H460 p53-/PTEN-cells. This could be possibly attributed to the limited efficiency of p53 and PTEN inhibition in NCI-H460 cells. Additionally, other inherent differences between the two cell lines could affect invasive capacity of COR-L23 cells.
Individually, PTEN and p53 act as negative regulators of CXCR4 and FAK expression. Namely, p53 represses transcription of both FAK and CXCR4, while PTEN dephosphorylates FAK and modulates CXCR4 expression through AKT signaling [11] [12] [13] [14] . However, the effects of simultaneous inhibition of p53 and PTEN on CXCR4 and FAK expression and activation of their signaling pathways are poorly studied. Djuzenova and colleagues observed that glioblastoma cell lines carrying mutations in p53 or PTEN exhibited a moderately increased level of total FAK and phospho-FAK (Ser910) while the phosphorylation of FAK (Tyr397) was abolished [32] . Our results showed that FAK gene expression was increased in COR-L23 cells while the level of pFAK (Tyr397) was elevated in both COR-L23 and NCI-H460 cells with functionally inhibited p53 and PTEN. CXCR4 mRNA and protein levels were increased in both COR-L23 and NCIH460cells with co-inhibited p53 and PTEN. Finally, the activity of downstream signaling molecules, pAKT and pERK, was increased in both cell lines with inactive p53 and PTEN, implying a key role of dual p53/PTEN inactivation for complete activation of CXCR4 and FAK signaling pathways. Similarly to the differences in invasive properties between the two cell lines, the levels of all investigated proteins were higher in COR-L23 cells. This could be also assigned to the incomplete Consequently, targeting CXCR4 and FAK in NSCLC cells with co-inactivated p53 and PTEN was used to suppress their invasive potential. Our results demonstrated that inhibition of CXCR4 and FAK with respective inhibitors significantly suppressed ability of NCI-H460 p53-/PTEN-and COR-L23 cells to migrate, invade and degrade gelatin. We observed that both WZ811 and PF-573228 achieved their anti-invasive effects in NCI-H460 p53-/PTEN-cells, at least partially, by reducing the activity of FAK and AKT. This is in accordance with the fact that CXCR4-induced migration can be mediated by PI3 kinase activation of FAK and/or AKT [8] while FAK can also function upstream of PI3K/AKT [35] . However, in COR-L23 cells only FAK inhibitor decreased level of pFAK and pAKT. The absence of any WZ811 effects on the studied proteins may suggest the involvement of other signaling pathways that need to be further elucidated. ERK pathway remained unchanged in both cell lines upon all treatments. This is in line with findings that CXCR4 signaling goes through the PI3K/Akt pathway when PTEN is inactive [36] and that FAK inhibition predominantly activates AKT rather than ERK signaling in lung cancer [37] .
Several in vivo studies, on sarcoma, breast, bladder and prostate carcinomas, have shown that dual p53/PTEN suppression causes highly aggressive phenotype with pronounced metastatic behavior that leads to a significantly decreased survival [38] [39] [40] [41] . Consequently, we extended the study to animal models of lung carcinoma, using orthotopic metastatic model of NSCLC in which we observed a tendency of decreased survival among mice with inoculated COR-L23 cells. Since NCI-H460 and COR-L23 cells did not show a statistically significant difference in regard to their tumorigenic potential in both NSG and SCID mice, shorter life span of COR-L23 tumor bearing animals could be attributed to COR-L23 tumor invasiveness and development of distant metastasis. Several targeted inhibitors, such as eEF2K and PARP/PI3K inhibitors, were successfully used to suppress growth of p53/PTEN deficient xenografts of different cancer types [41, 42] . However, our study is the first one that targeted CXCR4 and FAK in orthotopic models of p53/PTEN deficient tumors. We further observed a trend of slightly prolonged survival of animals with orthotopically inoculated COR-L23 cells upon treatments with WZ811 and PF-573228. These data suggest that CXCR4 and FAK can be useful as targets to suppress the aggressiveness of p53/PTEN deficient tumors. However, the lack of an appropriate statistical analysis in these experiments implies a need for a much more detailed evaluation of other CXCR4 and FAK inhibitors with better bioavailability, and possibly alternative methods of administration.
Overall, our study demonstrated that p53/PTEN deficient NSCLC cells have particularly invasive phenotype associated with hyperactivation of CXCR4 and FAK signaling pathways.
Our results point out the importance of subclassifying NSCLC patients according to p53 and PTEN functional status and to the potential of using CXCR4 and FAK inhibition to suppress metastatic spread of particularly aggressive p53/PTEN deficient tumors.
